New AI Blood Tests Could Catch Lung Cancer Years Earlier

At 69, Melinda McKnight of Arkansas is busier than ever, organizing fundraisers and spoiling her six grandchildren. Three years ago, a routine lung scan caught stage 1 cancer in her right lung, and today she's cancer-free.

Her story shows why early detection matters so much. When lung cancer is found at stage 1, up to 90% of patients survive five years or longer. Wait until the latest stages, and that number drops to just 10%.

Current screening using low-dose CT scans cuts lung cancer deaths by 20 to 24% among heavy smokers. The evidence is stronger than for any other cancer screening test, says oncologist Raymond Osarogiagbon at Baptist Cancer Center in Memphis.

But here's the problem: only 19% of eligible Americans ever get screened. Even worse, about half of people diagnosed with lung cancer never qualified for screening because they didn't smoke enough, quit too long ago, or fell outside the age range.

"We know the criteria are not perfect," says Osarogiagbon. Many doctors and patients simply don't know the screening exists, and some state insurance programs won't cover the cost.

Now researchers are developing better tools that could change everything. Blood-based biomarkers and artificial intelligence that analyzes scans more accurately could make screening safer and catch cancer even earlier. These innovations could expand screening to people who never smoked while reducing unnecessary biopsies that sometimes harm patients.

The shift is already happening in doctors' offices. Thoracic oncologist Jacob Sands at Dana-Farber Cancer Institute says early skepticism about lung cancer screening is fading as techniques improve. False-positive rates have dropped significantly since 2011, meaning fewer patients undergo unnecessary procedures.

The Ripple Effect

Better screening tools mean more stories like McKnight's. Thousands of people who would have faced late-stage diagnoses could instead catch cancer when it's most treatable. Communities wouldn't lose parents, grandparents, and friends in their prime years.

The technology could also reduce healthcare costs dramatically. Treating early-stage cancer requires less intensive therapy than advanced disease, saving both lives and resources that can help more patients.

As these AI and blood test innovations move from research labs to clinics, they promise to make lifesaving screening available to millions more people regardless of their smoking history.

McKnight knows she was lucky her doctor insisted on screening, even when another physician called it "overkill." Soon, catching cancer early won't require luck at all.